These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 10338049

  • 1. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants.
    Abdel-Mageed A, Graham-Pole J, Del Rosario ML, Longmate J, Ochoa S, Amylon M, Elfenbein GJ, Janiec J, Jansen J, Lazarus HM.
    Bone Marrow Transplant; 1999 May; 23(9):929-32. PubMed ID: 10338049
    [Abstract] [Full Text] [Related]

  • 2. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA.
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [Abstract] [Full Text] [Related]

  • 3. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
    Anderson D, DeFor T, Burns L, McGlave P, Miller J, Wagner J, Weisdorf D.
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ, Ho WG, Bartoni K, Champlin RE.
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.
    Rocha V, Wagner JE, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E.
    N Engl J Med; 2000 Jun 22; 342(25):1846-54. PubMed ID: 10861319
    [Abstract] [Full Text] [Related]

  • 8. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K, Downs K.
    Bone Marrow Transplant; 1995 Dec 22; 16(6):755-8. PubMed ID: 8750265
    [Abstract] [Full Text] [Related]

  • 9. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
    Kumar S, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Litzow MR.
    Bone Marrow Transplant; 2002 Aug 22; 30(3):161-5. PubMed ID: 12189534
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
    Klaesson S, Ringdén O, Ljungman P, Aschan J, Hägglund H, Winiarski J.
    Transplantation; 1995 Dec 15; 60(11):1225-30. PubMed ID: 8525515
    [Abstract] [Full Text] [Related]

  • 13. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar 15; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 14. [Intravenous immunoglobulins in bone marrow transplantation].
    Andolina M, Giorgi R, Maximova N, Comar M.
    Pediatr Med Chir; 1993 Mar 15; 15(4):347-8. PubMed ID: 8265452
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, Bacigalupo A.
    Haematologica; 1998 Feb 15; 83(2):132-7. PubMed ID: 9549924
    [Abstract] [Full Text] [Related]

  • 18. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
    List AF, Maziarz R, Stiff P, Jansen J, Liesveld J, Andrews F, Schuster M, Wolff S, Litzow M, Karanes C, Dahlberg S, Kirkhart B, Bianco JA, Singer JW.
    Bone Marrow Transplant; 2000 Feb 15; 25(3):283-91. PubMed ID: 10673700
    [Abstract] [Full Text] [Related]

  • 19. Graft-versus-host disease after marrow transplantation.
    Storb R.
    Prog Clin Biol Res; 1986 Feb 15; 224():139-57. PubMed ID: 3540990
    [Abstract] [Full Text] [Related]

  • 20. Time of onset, viral load, relapse, and duration of active cytomegalovirus infection in bone marrow transplant outcomes.
    Habib K, Lamia T, Amel L, Abdelrahmen A, Saloua L, Hana E, Amine S, Bechir Z, Tarek BO, Assia BH.
    Exp Clin Transplant; 2008 Mar 15; 6(1):67-73. PubMed ID: 18405248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.